Navire Pharma has a total of 40 patents globally, out of which 5 have been granted. Of these 40 patents, all patents are active. United States of America is where Navire Pharma has filed the maximum number of patents, followed by Mexico and Israel. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Navire Pharma.
Navire Pharma was founded in the year 2017. The Company is harnessing advances in our understanding of SHP2’s role in cancer signaling to develop novel therapies for rare and difficult-to-treat cancers.
Do read about some of the most popular patents of Navire Pharma which have been covered by us in this article and also you can find Navire Pharma patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Navire Pharma patent portfolio.
How many patents does Navire Pharma have?
Navire Pharma has a total of 40 patents globally. These patents belong to 8 unique patent families. Out of 40 patents, all patents are active.
How Many Patents did Navire Pharma File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Navire Pharma Applications Filed | Navire Pharma Patents Granted |
| 2023 | 2 | 3 |
| 2022 | 6 | – |
| 2021 | 12 | 2 |
| 2020 | 3 | – |
| 2019 | 17 | – |
How many Navire Pharma patents are Alive/Dead?
All the Patents were filed by Navire Pharma are Alive.
How Many Patents did Navire Pharma File in Different Countries?
Countries in which Navire Pharma Filed Patents
| Country | Patents |
| United States Of America | 4 |
| Mexico | 2 |
| Israel | 2 |
| Canada | 2 |
| China | 2 |
| India | 2 |
| Europe | 2 |
| Singapore | 2 |
| Taiwan | 2 |
| Brazil | 2 |
| Hong Kong (S.A.R.) | 2 |
| South Africa | 2 |
| Australia | 2 |
| Costa Rica | 1 |
| Philippines | 1 |
| Peru | 1 |
| Chile | 1 |
| Colombia | 1 |
| Indonesia | 1 |
Where are Research Centres of Navire Pharma Patents Located?
The Research Centre for all the Navire Pharma patents is the United States of America.
What Percentage of Navire Pharma US Patent Applications were Granted?
Navire Pharma (Excluding its subsidiaries) has filed 4 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 2 have been granted leading to a grant rate of 100.0%.
Below are the key stats of Navire Pharma patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Navire Pharma?
| Law Firm | Total Applications | Success Rate |
| Mintz Levin Bridgebio | 3 | 100.00% |
| Mintz Levin Bms Navire | 1 | 0% |
List of Navire Pharma Patents
| Navire Pharma Patents | Title |
| US11104675B2 | Ptpn11 Inhibitors |
| US10954243B2 | Substituted Heterocyclic Inhibitors Of Ptpn11 |
| US20220041594A1 | Ptpn11 Inhibitors |
| US20210317122A1 | Substituted Heterocyclic Inhibitors Of Ptpn11 |
| EP3787627A4 | Substituted Heterocyclic Inhibitors Of Ptpn11 |
| EP3833670A1 | 6-(4-Amino-3-Methyl-2-Oxa-8-Azaspiro[4.5]Decan-8-Yl)-3-(2,3-Dichlorophenyl)-2-Methylpyrimidin-4(3H)-One Derivatives And Related Compounds As Ptpn11 (Shp2) Inhibitors For Treating Cancer |
| CN112601750B | Ptpn11 (Shp2) Inhibitors |
| CN112351780A | Substituted Heterocyclic Inhibitors Of Ptpn11 |
| WO2023205794A1 | Combination Therapy Using A Pyrimidone Derivative As Ptpn11 Inhibitor And A Pd-1/Pd-L1 Inhibitor And Its Use In The Treatment Of Cancer |
| WO2023205795A1 | Combination Therapy Using A Substituted Pyrimidin-4(3H)-One And Nivolumab As Well As Its Use In The Treatment Of Cancer |
| WO2023059785A9 | Substituted Pyrimidin-4(3H)-Ones For Use In Treating Cancer |
| WO2023056015A1 | Combination Therapy Using A Ptpn11 Inhibitor And An Egfr Inhibitor |
| WO2023056020A1 | Combination Therapy Using A Ptpn11 Inhibitor And A Kras G12C Inhibitor |
| WO2023056037A1 | Combination Therapy Using Substituted Pyrimidin-4(3H)-Ones And Sotorasib |
| CA3109181A1 | 6-(4-Amino-3-Methyl-2-Oxa-8-Azaspiro[4.5]Decan-8-Yl)-3-(2,3-Dichlorophenyl)-2-Methylpyrimidin-4(3H)-One Derivatives And Related Compounds As Ptpn11 (Shp2) Inhibitors For Treating Cancer |
| CA3099151A1 | Substituted Heterocyclic Inhibitors Of Ptpn11 |
| AU2019319971A1 | 6-(4-Amino-3-Methyl-2-Oxa-8-Azaspiro(4.5)Decan-8-Yl)-3-(2,3-Dichlorophenyl)-2-Methylpyrimidin-4(3H)-One Derivatives And Related Compounds As Ptpn11 (Shp2) Inhibitors For Treating Cancer |
| AU2019263294A1 | Substituted Heterocyclic Inhibitors Of Ptpn11 |
| IL280701A | 6-(4-Amino-3-Methyl-2-Oxa-8-Azaspiro[4.5]Decan-8-Yl)-3-(2,3-Dichlorophenyl)-2-Methylpyrimidin-4(3H)-One Derivatives And Related Compounds As Ptpn11 (Shp2) Inhibitors For Treating Cancer |
| IL278297A | Substituted Heterocyclic Inhibitors Of Ptpn11 |
| HK40039574A | 6-(4-Amino-3-Methyl-2-Oxa-8-Azaspiro[4.5]Decan-8-Yl)-3-(2,3-Dichlorophenyl)-2-Methylpyrimidin-4(3H)-One Derivatives And Related Compounds As Ptpn11 (Shp2) Inhibitors For Treating Cancer |
| HK40037519A | Substituted Heterocyclic Inhibitors Of Ptpn11 |
| MX402551B | Compounds Derived From Pyrazolopyrazines As Inhibitors Of The Protein-Tyrosine Phosphatase Type 11 Non-Receptor Ptpn11(Shp2) For The Treatment Of Diseases Caused By One Or Mutations Of Ptpn11, Such As Cancer |
| CL66832B | Pyrimidin-4-One Derived Compounds, Ptpn11 Inhibitors; Composition; Use In Noonan Syndrome, Leopard Syndrome And Cancer (Pph). |
| TW202339729A | Combination Therapy Using A Ptpn11 Inhibitor And A Kras G12C Inhibitor |
| TW202339748A | Treatment Methods With Substituted Pyrimidin-4(3H)-Ones |
| PH12021550268A1 | 6-(4-Amino-3-Methyl-2-Oxa-8-Azaspiro[4.5]Decan-8-Yl)-3-(2,3-Dichlorophenyl)-2-Methylpyrimidin-4(3H)-One Derivatives And Related Compounds As Ptpn11 (Shp2) Inhibitors For Treating Cancer |
| ID2021PID07141A | 6-(4-Amino-3-Methyl-2-Okxe-8-Azaspiro[4.5]Dean-8-Il)-3-(2,3-Dichlorophenyl)-2-Methylpyrimidine-4(3H)-Derivatives On And Related Compounds As Ptpn11 (Shp2) Inhibitors To Treat Cancer |
| CR20210132A | 6-(4-Amino-3-Methyl-2-Oxa-8-Azaspiro[4.5]Decan-8-Yl)-3-(2,3-Dichlorophenyl)-2-Methylpyrimidin-4(3H)-One Derivatives And Related Compounds As Ptpn11 (Shp2) Inhibitors For Treating Cancer |
| MX2021001608A | 6-(4-Amino-3-Methyl-2-Oxa-8-Azaspiro [4.5]Decan-8-Yl)-3-(2,3-Dich Lorophenyl)-2-Methylpyrimidin-4(3H)-One Derivatives And Related Compounds As Ptpn11 (Shp2) Inhibitors For Treating Cancer. |
| CO20210003074A2 | 6-(4-Amino-3-Methyl-2-Oxa-8-Azaspiro[4.5]Decan-8-Yl)-3-(2,3-Dichlorophenyl)-2-Methylpyrimidin-4(3H)-One Derivatives And Related Compounds As Ptpn11 (Shp2) Inhibitors For Cancer Treatment |
| BR112020022224A2 | Heterocyclic Substitute Ptpn11 Inhibitors |
| PE0010502021A1 | Ptpn11 Inhibitors |
| BR112021002327A2 | 6-(4-Amino-3-Methyl-2-Oxa-8-Azaespiro[4,5]Decan-8-Yl)-3-(2,3-Dichlorophenyl)-2-Methylpyrimidin-4(3H) Derivatives -Ona And Related Compounds As Ptpn11(Shp2) Inhibitors For The Treatment Of Cancer |
| IN202117009157A | 6-(4-Amino-3-Methyl-2-Oxa-8-Azaspiro[4.5]Decan-8-Yl)-3-(2,3-Dichlorophenyl)-2-Methylpyrimidin-4(3H)-One Derivatives And Related Compounds As Ptpn11 (Shp2) Inhibitors For Treating Cancer |
| ZA202101449A | 6-(4-Amino-3-Methyl-2-Oxa-8-Azaspiro[4.5]Decan-8-Yl)-3-(2,3-Dichlorophenyl)-2-Methylpyrimidin-4(3H)-One Derivatives And Related Compounds As Ptpn11 (Shp2) Inhibitors For Treating Cancer |
| SG11202100199UA | 6-(4-Amino-3-Methyl-2-Oxa-8-Azaspiro[4.5]Decan-8-Yl)-3-(2,3-Dichlorophenyl)-2-Methylpyrimidin-4(3H)-One Derivatives And Related Compounds As Ptpn11 (Shp2) Inhibitors For Treating Cancer |
| IN202017051065A | Substituted Heterocyclic Inhibitors Of Ptpn11 |
| SG11202010822SA | Substituted Heterocyclic Inhibitors Of Ptpn11 |
| ZA202006763A | Substituted Heterocyclic Inhibitors Of Ptpn11 |
What are Navire Pharma key innovation segments?
What Technologies are Covered by Navire Pharma?
The chart below distributes patents filed by Navire Pharma